Bristol-Myers Squibb Company (NYSE:BMY) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a report issued on Saturday, June 10th. Several other research analysts have also weighed in on BMY. …
BNS1mon
Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $64.00 price objective on shares of Bristol-Myers Squibb Company in a research note on Monday, June 5th. One investment analyst has rated the stock with a sell rating, twelve …
The stock of RPC, Inc. UBS maintained the shares of BMY in report on Friday, April 29 with "Buy" rating. The rating was upgraded by Berenberg to "Buy" on Friday, January 22. See Hovnanian Enterprises, Inc. Of Vermont holds 0.43% of its …
Investors in Bristol-Myers Squibb Co. (NYSE: BMY) saw new options become available today, for the October 30th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BMY options chain for the …
[at Wall St. Cheat Sheet] – Bristol-Myers has a 42 percent positive surprise history, having topped the whisper in 11 of …
BMO Capital Markets reiterated their market perform rating on shares of Bristol-Myers Squibb Co (NYSE:BMY) in a research note issued to investors on Tuesday. They currently have a $45.00 target price on the biopharmaceutical …
Analysts reviewing Bristol-Myers Squibb Company have recently updated their recommended buy/sell ratings and price targets on the stock. Based on their most recently released notes to investors, 7 analysts have a rating of “buy”, 3 …
Bristol-Myers Squibb Inc.'s stock BMY, -0.18% took an afternoon tumble Friday, to close down 6.6% on heavy volume, as investors expressed disappointment over the drugmaker's updates to studies of its cancer treatment Opdivo. The stock
This leaves the door wide open for downgrades, which could pressure MNK shares even lower. Bristol-Myers Squibb stock is also near the bottom of the SPX, down 4.5% at $52.51. The company presented an update for its Opdivo-Yervoy …
Shareholders of Bristol-Myers Squibb Co. (BMY) looking to boost their income beyond the stock's 2.8% annualized dividend yield can sell the January 2018 covered call at the $65 strike and collect the premium based on the $1.77 bid, …